(Q38028778)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825216%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Pushing the limits of targeted therapy in chronic myeloid leukaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825216%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825216%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Thomas O'Hare

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825216%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Matthew S Zabriskie

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825216%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Michael W Deininger

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825216%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

language of work or name

English

0 references

publication date

24 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825216%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825216%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825216%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825216%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

513-526

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22825216%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc3317

8 February 2020

exact match

0 references

cites work

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling

31 March 2020

1 reference

miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts

31 March 2020

1 reference

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia

31 March 2020

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

31 March 2020

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

31 March 2020

1 reference

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

31 March 2020

1 reference

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

31 March 2020

1 reference

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

31 March 2020

1 reference

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

31 March 2020

1 reference

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

31 March 2020

1 reference

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

31 March 2020

1 reference

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

31 March 2020

1 reference

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

31 March 2020

1 reference

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

31 March 2020

1 reference

Chronic myeloid leukemia: mechanisms of blastic transformation

31 March 2020

1 reference

Autoinhibition of Bcr-Abl through its SH3 domain

31 March 2020

1 reference

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

31 March 2020

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

31 March 2020

1 reference

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

31 March 2020

1 reference

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

31 March 2020

1 reference

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

31 March 2020

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

31 March 2020

1 reference

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

31 March 2020

1 reference

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain

31 March 2020

1 reference

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

31 March 2020

1 reference

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

31 March 2020

1 reference

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

31 March 2020

1 reference

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

31 March 2020

1 reference

Activation of tyrosine kinases by mutation of the gatekeeper threonine

31 March 2020

1 reference

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

31 March 2020

1 reference

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase includ

31 March 2020

1 reference

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

31 March 2020

1 reference

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

31 March 2020

1 reference

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile

31 March 2020

1 reference

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants

31 March 2020

1 reference

Gastrointestinal stromal tumours: origin and molecular oncology.

31 March 2020

1 reference

Structural basis for the autoinhibition of c-Abl tyrosine kinase

31 March 2020

1 reference

A myristoyl/phosphotyrosine switch regulates c-Abl

31 March 2020

1 reference

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

31 March 2020

1 reference

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

31 March 2020

1 reference

Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.

31 March 2020

1 reference

Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay

31 March 2020

1 reference

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

31 March 2020

1 reference

Disruption of Bcr-Abl coiled coil oligomerization by design

31 March 2020

1 reference

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis

31 March 2020

1 reference

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check

31 March 2020

1 reference

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

31 March 2020

1 reference

Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis

31 March 2020

1 reference

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib

31 March 2020

1 reference

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

31 March 2020

1 reference

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

31 March 2020

1 reference

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

31 March 2020

1 reference

Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy

31 March 2020

1 reference

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

31 March 2020

1 reference

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

31 March 2020

1 reference

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

31 March 2020

1 reference

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

31 March 2020

1 reference

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

31 March 2020

1 reference

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia

31 March 2020

1 reference

Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells

31 March 2020

1 reference

Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia

31 March 2020

1 reference

Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.

31 March 2020

1 reference

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation

31 March 2020

1 reference

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.

31 March 2020

1 reference

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.

31 March 2020

1 reference

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

31 March 2020

1 reference

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells

31 March 2020

1 reference

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy

31 March 2020

1 reference

An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia

31 March 2020

1 reference

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

31 March 2020

1 reference

Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein

31 March 2020

1 reference

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

31 March 2020

1 reference

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

31 March 2020

1 reference

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

31 March 2020

1 reference

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib

31 March 2020

1 reference

Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells

31 March 2020

1 reference

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

31 March 2020

1 reference

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy

31 March 2020

1 reference

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

31 March 2020

1 reference

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

31 March 2020

1 reference

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

31 March 2020

1 reference

MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

31 March 2020

1 reference

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

31 March 2020

1 reference

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

31 March 2020

1 reference

Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations

31 March 2020

1 reference

The concept of synthetic lethality in the context of anticancer therapy

31 March 2020

1 reference

Exploiting synthetic lethal interactions for targeted cancer therapy

31 March 2020

1 reference

Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors

31 March 2020

1 reference

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

31 March 2020

1 reference

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

31 March 2020

1 reference

Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia

31 March 2020

1 reference

BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.

31 March 2020

1 reference

HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells

31 March 2020

1 reference

PML targeting eradicates quiescent leukaemia-initiating cells

31 March 2020

1 reference

Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate

31 March 2020

1 reference

Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.

31 March 2020

1 reference

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells

31 March 2020

1 reference

Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib

31 March 2020

1 reference

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

31 March 2020

1 reference

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

31 March 2020

1 reference

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib

31 March 2020

1 reference

Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib

31 March 2020

1 reference

Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells

31 March 2020

1 reference

A role for Wnt signalling in self-renewal of haematopoietic stem cells

31 March 2020

1 reference

Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo

31 March 2020

1 reference

Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML.

31 March 2020

1 reference

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

31 March 2020

1 reference

Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation

31 March 2020

1 reference

Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation

31 March 2020

1 reference

Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells

31 March 2020

1 reference

CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression

31 March 2020

1 reference

Targeting the Wnt/β-catenin signaling pathway in human cancers

31 March 2020

1 reference

Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation

31 March 2020

1 reference

Hedgehog signaling is dispensable for adult hematopoietic stem cell function

31 March 2020

1 reference

Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation

31 March 2020

1 reference

Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia

31 March 2020

1 reference

Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells.

31 March 2020

1 reference

TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

31 March 2020

1 reference

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

31 March 2020

1 reference

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition

31 March 2020

1 reference

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

31 March 2020

1 reference

Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

31 March 2020

1 reference

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

31 March 2020

1 reference

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

31 March 2020

1 reference

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

31 March 2020

1 reference

Am"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis.

31 March 2020

1 reference

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

31 March 2020

1 reference

Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase

31 March 2020

1 reference

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

31 March 2020

1 reference

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

31 March 2020

1 reference

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

31 March 2020

1 reference

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

31 March 2020

1 reference

Hematopoiesis: a human perspective

31 March 2020

1 reference

Evaluation at single cell level of residual Philadelphia negative hemopoietic stem cells in chronic phase CML patients

31 March 2020

1 reference

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

31 March 2020

1 reference

Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function

31 March 2020

1 reference

How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia

31 March 2020

1 reference

Chronic myeloid leukaemia as a model of disease evolution in human cancer

31 March 2020

1 reference

Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells.

31 March 2020

1 reference

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

31 March 2020

1 reference

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia

31 March 2020

1 reference

Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells

31 March 2020

1 reference

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

31 March 2020

1 reference

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

31 March 2020

1 reference

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

31 March 2020

1 reference

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

31 March 2020

1 reference

Practical monitoring of chronic myelogenous leukemia: when to change treatment

31 March 2020

1 reference

Response definitions and European Leukemianet Management recommendations

31 March 2020

1 reference

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

31 March 2020

1 reference

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

31 March 2020

1 reference

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

31 March 2020

1 reference

Targeting hedgehog in hematologic malignancy.

31 March 2020

1 reference

Gene expression changes associated with progression and response in chronic myeloid leukemia

31 March 2020

1 reference

Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia

31 March 2020

1 reference

12 December 2020

Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization

1 reference

12 December 2020

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)

1 reference

12 December 2020

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

1 reference

12 December 2020

Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia

1 reference

12 December 2020

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors

1 reference

12 December 2020